Blog

- August 21, 2025

FDA clearance of Salix® Coronary Plaque module

PERTH, Australia, Aug. 21, 2025 /PRNewswire/ — Artrya Limited (ASX: AYA) (Artrya or the Company), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, is pleased to announce it has received 510(k) clearance from the U.S. Food and Drug Administration (the FDA) for Artrya’s proprietary, Salix® Coronary Plaque module.

Read More »

Fat-trapping microbeads provide drug-free weight loss in rats

Weight-loss interventions, including gastric bypass surgery and drugs that prevent dietary fat absorption, can be invasive or have negative side effects. Now, researchers have developed edible microbeads made from green tea polyphenols, vitamin E and seaweed that, when consumed, bind to fats in the gastrointestinal tract.

Read More »